Pediatric Praziquantel Program

Develop new pediatric formulation to treat young children for schistosomiasis.

Pediatric PZQ Consortium

Schistosomiasis, also known as bilharzia and endemic in 78 developing countries, is a chronic inflammatory disease caused by parasitic worms. It is the second most prevalent parasitic disease after malaria, affecting nearly 240 million people worldwide, including 100 million children, with 90% of cases occurring in sub-Saharan Africa. Commonly associated with poor sanitation and no access to drinking water, schistosomiasis causes local and systemic effects, including progressive damage to organs; untreated, the disease can lead to anemia, stunting and reduced learning ability, and can be fatal.

The current gold standard treatment for schistosomiasis is Merck’s Praziquantel, an oral anti-helminthic proven to be safe and effective. The standard recommended Praziquantel treatment is available in oral immediate release tablets for adults and school-age children; a pediatric formulation suitable for treating younger children is lacking.

The Pediatric Praziquantel Consortium, launched in 2012, is an international, non-profit public-private partnership and combines the best science and most experienced public and private partners to develop, manufacture, register and launch a new pediatric formulation of praziquantel.


  • Bill & Melinda Gates Foundation (B&MGF)

    United States | Staff size: Unknown
    They are focused on the areas of greatest need, on the ways in which they can do the most good.


  • Farmanguinhos

    Goods Supplier
    Brazil | Staff size: Unknown

    The Institute of Drug Technology (Farmanguinhos) is currently the largest official pharmaceutical laboratory linked to the Ministry of Health. Farmanguinhos produces over one...

  • Global Health Innovative Technology Fund (GHIT Fund)

    Funding Agencies
    Japan | Staff size: 26-50

    The Global Health Innovative Technology Fund (GHIT Fund) is a public-private partnership that leverages Japanese innovation, investment, and leadership to advance the development of new health...

  • SimCyp

    Staff size: Unknown
  • Swiss Tropical and Public Health Institute (Swiss TPH)

    Institute, Development Consulting
    Switzerland | Staff size: 501-1000

    The Swiss Tropical and Public Health Institute (Swiss TPH) is a world-leading institution in health research, training and services. It improves, maintains and promotes the health of individuals...

  • TI Pharma (Top Institute Pharma)

    Implementing NGO
    Netherlands | Staff size: Unknown

    Top Institute Pharma (TI Pharma) is a public-private partnership in which academic and business worlds work together on groundbreaking, multidisciplinary research aimed at improving the...

More Resources

Key Information

  • Start Date 2012